Exenatide

Phase 3Completed

1 views this week 0 watching⚡ Active

Interest: 40/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

Phase 3

Approved

Indication / Disease

Coronary Artery Disease

Conditions

Coronary Artery Disease, Decreased Left Ventricular Function

Trial Timeline

Jun 1, 2011 → Dec 1, 2014

NCT ID

NCT01373216

About Exenatide

Exenatide is a phase 3 stage product being developed by Eli Lilly for Coronary Artery Disease. The current trial status is completed. This product is registered under clinical trial identifier NCT01373216. Target conditions include Coronary Artery Disease, Decreased Left Ventricular Function.

What happened to similar drugs?

20 of 20 similar drugs in Coronary Artery Disease were approved

Approved (20) Terminated (2) Active (0)

✅EvolocumabHeartFlowApproved

✅Clopidogrel treatment groupYuhanApproved

✅high-dose rosuvastatin + low-dose rosuvastatin plus ezetimibeYuhanApproved

✅statins, ezetimibe + Combination therapyYuhanApproved

✅Modification of Prasugrel based on a biological assay + prasugrel / clopidogrelDaiichi SankyoApproved

✅PrasugrelDaiichi SankyoApproved

✅Prasugrel + ClopidogrelDaiichi SankyoApproved

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (6)

NCT ID	Phase	Status	Start	Completion	Indication
NCT01373216	Phase 3	Completed	Jun 1, 2011	Dec 1, 2014	Coronary Artery Disease
NCT01056549	Pre-clinical	Completed	Jan 1, 2010	Sep 1, 2011	Hyperlipidemia
NCT00753896	Phase 3	Completed	Oct 1, 2008	Nov 1, 2009	Type 2 Diabetes
NCT00529204	Phase 2	Terminated	Oct 1, 2007	Feb 1, 2010	Diabetes Complications
NCT00516048	Phase 3	Completed	Aug 1, 2007	Apr 1, 2008	Type 2 Diabetes Mellitus
NCT01876849	Phase 3	Completed	Dec 1, 2003	Jul 1, 2008	Type 2 Diabetes Mellitus

Competing Products

20 competing products in Coronary Artery Disease

See all competitors

Product	Company	Stage	Hype Score
Rosuvastatin 40mg + Placebo	HeartFlow	Pre-clinical	27
Evolocumab	HeartFlow	Approved	29
High intensity lipid lowering	HeartFlow	Pre-clinical	20
Clopidogrel treatment group	Yuhan	Approved	50
YH14659 + clopidogrel & aspirin	Yuhan	Phase 1	29
high-dose rosuvastatin + low-dose rosuvastatin plus ezetimibe	Yuhan	Approved	43
Sarpogrelate + Aspirin + Clopidogrel + Placebo (for Sarpogrelate)	Yuhan	Phase 3	40
statins, ezetimibe + Combination therapy	Yuhan	Approved	50
YH14659 + clopidogrel & aspirin	Yuhan	Phase 1	29
Modification of Prasugrel based on a biological assay + prasugrel / clopidogrel	Daiichi Sankyo	Approved	43
clopidogrel + prasugrel	Daiichi Sankyo	Phase 1	21
Prasugrel	Daiichi Sankyo	Approved	43
ADP receptor inhibitors	Daiichi Sankyo	Pre-clinical	26
Pactimibe, CS-505	Daiichi Sankyo	Phase 2	35
Prasugrel + Clopidogrel	Daiichi Sankyo	Phase 2	35
prasugrel + clopidogrel	Daiichi Sankyo	Phase 1	29
Prasugrel + Clopidogrel	Daiichi Sankyo	Approved	43
Triple oral lipid lowering treatment	Daiichi Sankyo	Phase 3	47
Placebo + Prasugrel	Daiichi Sankyo	Phase 3	40
30-day DAPT + Guideline-directed therapy	Daiichi Sankyo	Approved	50